These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27743681)

  • 1. Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience.
    Valencia ME; Martín-Carbonero L; Moreno V; Bernardino JI; Montes ML; Montejano R
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Jan; 36(1):29-33. PubMed ID: 27743681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
    Llibre JM; Cozzi-Lepri A; Pedersen C; Ristola M; Losso M; Mocroft A; Mitsura V; Falconer K; Maltez F; Beniowski M; Vullo V; Hassoun G; Kuzovatova E; Szlavik J; Kuznetsova A; Stellbrink HJ; Duvivier C; Edwards S; Laut K; Paredes R;
    Medicine (Baltimore); 2016 Oct; 95(40):e5020. PubMed ID: 27749561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Ward D; Zhao HH; Ross LL; Shaefer MS;
    HIV Clin Trials; 2012; 13(5):233-44. PubMed ID: 23134624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
    Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
    Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
    J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
    Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
    PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
    Tsai MS; Chang SY; Lin SW; Kuo CH; Sun HY; Wu BR; Tang SY; Liu WC; Su YC; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Dec; 50(6):789-797. PubMed ID: 26857335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
    Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
    J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
    Sarkar A; Balogun K; Guzman Lenis MS; Acosta S; Mount HT; Serghides L
    PLoS One; 2020; 15(11):e0242513. PubMed ID: 33211746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.